Introduction: Impaired natural killer (NK) cell activity contributes to viral persistence in HCV infection. Recent studies demonstrated that in tumors regulatory T cells (Treg) -via secreting TGF-beta1 -down-regulate NKG2D killer activator receptor and are responsible for poor NK cytoxicity. Since in chronic hepatitis C plasma TGF-beta1 level is increased, we analyzed the expression of NKG2D on NK and T cells and its correlation with the percentage of Treg cells and TGF-beta1 levels.
Methods: The peripheral CD4+CD25high+ Treg cells, NKG2D+ NK and T cells were determined by FACS, plasma TGF-beta1 levels by ELISA. Forty three patients with active chronic hepatitis C, 10 sustained virological responders (SVR) and 15 healthy controls were enrolled.
Results: In patients with chronic hepatitis C the NKG2D expression was down-regulated both on NK (7,9 vs. 20,9%) and T cells (18 vs. 26,3%) compared to controls. Impaired expression of NKG2D was associated with increased proportion of CD4+CD25high+ Treg cells (4,6 vs. 3,1%) and increased TGF-beta1 levels (15 vs.9 pg/ml) compared to controls. TGF-beta1 inversely correlated with NKG2D expression on NK cells. In SVR group, the percentage of Treg cells (1,7 ± 0,2%), TGF-beta1 levels (11,6 pg/ml) and NKG2D expression (NK:17%, T:20,9%) were comparable to controls.
Discussion/Conclusion: Our data suggest that TGF-beta1 -secreted by regulatory T cells -may be responsible for impaired NK cell function via down-regulating NKG2D. Thus, TGF-beta1 antagonism or soluble NKG2D ligands may provide the basis of a novel immunotherapy to improve the function of NK and T cells in chronic hepatitis C. Objective: A nation-wide retrospective analysis has been performed in order to assess the efficacy of antiviral therapy for patients with chronic hepatitis B and C representing the entire population that needed treatment in Hungary, during a seven-year period. In addition, results of a prospective study including patients with chronic hepatitis C are also presented.
Patients and Methods: Of 220 patients with hepatitis B, 112 were treated with standard interferon-alpha (IFN), 23 with pegylated interferon-alpha-2a (PEG-IFN) and 85 with lamivudine (LAM), and the ratio of HBeAg seroconversion and/or undetectable HBV-DNA has been assessed. Of 2442 patients with hepatitis C, 333 were treated with IFN monotherapy, 1122 with IFN + ribavirin (RBV) and 987 with PEG-IFN + RBV for 6-12 months. In the prospective study, 69 patients with chronic hepatitis C were enrolled and treated with PEG-IFN alfa-2a + RBV. The rate of sustained virological response (SV), the predictors of outcome and the adverse effects of treatment were evaluated.
Results: For HBV patients IFN, PEG-IFN and LAM provided 31, 30, and 33% SVR rate, respectively. In chronic hepatitis C, 13th International Congress on Infectious Diseases Abstracts, Poster Presentations e429 a continuous improvement was noted in sustained virological response, from 13% with IFN monotherapy to 31% with PEG-IFN + RBV, while even a 48% sustained virological response has been achieved in the prospective trial. The predictors of outcome were the 4-week 'rapid' and 12-week 'early' virological responses, female gender, age, BMI and adherence. The most frequent complications of the treatment were cytopenia, haemolysis and depression, occurring in 9% of patients.
Conclusion: Unlike in HBV infection, in HCV hepatitis the efficacy of antiviral treatment has gradually improved in our everyday clinical practice. To manage the growing populations of hard-to-treat patients with chronic viral hepatitis, there is a need for more effective treatment modalities, including optimised, individualised dosing and novel antiviral agents. Aims: Since in the outcome of chronic hepatitis C virus (HCV) infection the progression of hepatic fibrosis is essential, and interferon (IFN) treatment is supposed to inhibit fibrogenesis, we wanted to compare changes in three noninvasive fibrosis markers in chronic HCV hepatitis.
Methods: Plasma levels of TGF-beta1 and hyaluronic acid (HA) were determined by ELISA, procollagen-III-peptide (P-III-P) levels by RIA in 49 patients with chronic hepatitis C before the antiviral treatment and 1, 3, 6 and 12 months thereafter. Twenty two patients became responders (R), 27 patients were non-responders (NR). Thirty healthy controls were also studied. Correlation between TGF-beta1, HA, P-III-P levels and the histological activity and the fibrosis score in liver biopsy was evaluated.
Results: Pretreatment plasma TGF-beta1, HA and P-III-P levels were significantly (p < 0,01) increased in both responder and non-responder patients compared to controls. HA levels correlated with fibrosis score, TGF-beta1 with histological activity index. PEG-IFN + ribavirin treatment decreased both TGF-beta1 and HA levels, not only in responders but also in non-responders. The reduction of fibrosis marker levels was more considerable after 6 months of antiviral therapy, and remained sustained even 6 months after the treatment. No correlation was found betwen fibrosis markers and HCV RNA levels. Infections with HBV and HCV are the most common cause of chronic hepatitis and their consequence may be liver cirrhosis and/or hepatocellular carcinoma. Co-infection with these viruses is relatively common and it remains serious epidemiological and clinical problem.
Objective: Evaluation of impact of co-infection with HBV and HCV on clinical picture of chronic hepatitis. Results: Median value of viral load in group A was 1,4 × 10 6 and in group B was 1,0 × 10 6 (p > 0,05). There were no statistical correlation of GOT, GPT, GGTP and PLT values in these two groups. Grading in group A was 1,64 and in group B was 1,62 (p > 0,5). Relevant differences in fibrosis stage was observed between the groups -staging in group A was 1,87 and in group B 1,37 (p < 0,05)).
Conclusions: Past HBV infection and possible minireplication has no impact on HCV viremia. Fibrosis of the liver was surprisingly higher in HCV monoinfection patients. Further investigation in large and homogenous groups of patients are needed. 
